Indian Journal of Public Health Research & Development

Abstract

Aim: To evalaute the pleiotropic effects of metfromin by measuring the Hs-CRP in newly diagnosed type 2 diabetes mellitus patients.

Materials and Method: A total of 70 patients were enrolled in the study, and out of that 50 patients who fulfilled the eligibility criteria were included in the study. And after randomization and obtaining the informed consent,50 patients were subjected to the trial drug-tablet Metformin 500mg twice daily for a period of 6 months and the patients were advised to follow at 3 and 6 months and hs-crp levels were measured at baseline and followup and patients were monitored for adverse drug events.

Results: hs-CRP baseline value expressed as Mean±SD was 3.4±1.16 mg/L . After 3 months of metformin therapy, hs-CRP reduced to 2.93±0.9 mg/L. After 6 months of metformin therapy, hs-CRP effectively reduced to 1.7±0.81 mg/L. hs-CRP levels were lowered after 6 months of treatment. Treatment with Metformin showed effective reduction in hs-CRP values comparatively between hs-CRP baseline values and hs-CRP values at sixth month were significant (P<0.05).

Conclusion: To conclude with the above findings shows that there was significant reduction in hs-CRP after six of therapy with metformin and hence proving its pleiotropic effects and hence apart from it’s a antidiabetic agent it proves its beneficial cardioprotective role in patients with newly diagnosed type 2 diabetes mellitus patients.

Keywords

Full Text

Abstract

Aim: To evaluate the efficacy of metformin monotherapy in newly diagnosed type 2 mellitus patients by assessing the hba1c reduction percentage and thereby preventing the incidence of macrovascular complications.

Materials and Method: A total of 50 type 2 diabetes mellitus patients were included in the study.and after obtaining the informed consent the patients were advised to take Tablet metformin 500mg twice daily and hba1c were done at baseline, 3 and 6 months of the study period and the patients were assessed periodically and if any adverse events were reported it was recorded and manged promptly.

Results: HBA1C baseline value expressed as Mean±SD was 7.966±0.85 %. After 3 months of metformin therapy, HBA1C mean obtained was 7.53±0.83 %. After 6 months of metformin therapy, HBA1C improved to 6.8±0.93. Treatment with Metformin showed effective reduction in HBA1C values comparatively between HBA1C baseline values and HBA1C values at sixth month were statistically significant(P<0.05).

Conclusion: From the above results the current study shows significant reduction in hba1c values after six months of metformin therapy and this proves that metformin is a sole antidiabetic agent started as monotherapy in newly diagnosed diabetic patients the incidence of macrovascular complications can be prevented at the intial stage of the disease.

Keywords

Full Text